Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR New Investigator

McGill University

$300,000.00

Improving Outcomes in Frail Older Adults with Cardiovascular Disease

EF 2015-16

Résumé
The aging population has redefined the field of heart disease from single-system disease-oriented care to multi-faceted patient-oriented care. Frailty is a syndrome seen mainly in older adults that is central to the patient-oriented care model as it reflects the individual patient's reserves and resiliency to stressful events such as surgery. My research has shown that frail patients suffer a 3-fold increase in death, complications, and poor recovery of physical function after heart surgery and other invasive heart procedures. However, existing tools to measure frailty are limited by low specificity in hospitalized patients and ambiguity about their actionable ramifications - this is a critical barrier that has stifled the advancement of treatment strategies. The solution that I am proposing is to use a different marker to measure frailty, one that has the potential to be treated in clinical practice, namely - sarcopenia. Sarcopenia, "the biological substrate of frailty", is the age-related loss of muscle mass and strength. Various criteria exist to define it, some using special scales and others using bone density scanners, but these have not been adequately assessed in patients with heart disease who may have issues such as fluid retention that can cause inaccurate measurements. Thus, I will compare the accuracy and prognostic value of various criteria to determine how we should optimally diagnose sarcopenia in patients with heart disease. Then, I will identify patients who are referred for heart surgery and have low muscle mass and strength (sarcopenia) to test a targeted treatment - a specialized protein supplement beverage - which was designed to stimulate muscle building in older adults, and, I hypothesize, will improve their recovery of physical function and other outcomes after the heart surgery procedure.
Programme
CIHR New Investigator
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
340917
Name
Afilalo Jonathan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Health Professional Awards - New Investigators
Projecttitle
Improving Outcomes in Frail Older Adults with Cardiovascular Disease
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Aortic Valve Replacement; Cardiac Surgery; Cardiovascular Disease; Coronary Artery Bypass; Frailty; Mortality; Outcomes; Physical Performance; Quality Of Life; Sarcopenia
Abstract
The aging population has redefined the field of heart disease from single-system disease-oriented care to multi-faceted patient-oriented care. Frailty is a syndrome seen mainly in older adults that is central to the patient-oriented care model as it reflects the individual patient's reserves and resiliency to stressful events such as surgery. My research has shown that frail patients suffer a 3-fold increase in death, complications, and poor recovery of physical function after heart surgery and other invasive heart procedures. However, existing tools to measure frailty are limited by low specificity in hospitalized patients and ambiguity about their actionable ramifications - this is a critical barrier that has stifled the advancement of treatment strategies. The solution that I am proposing is to use a different marker to measure frailty, one that has the potential to be treated in clinical practice, namely - sarcopenia. Sarcopenia, "the biological substrate of frailty", is the age-related loss of muscle mass and strength. Various criteria exist to define it, some using special scales and others using bone density scanners, but these have not been adequately assessed in patients with heart disease who may have issues such as fluid retention that can cause inaccurate measurements. Thus, I will compare the accuracy and prognostic value of various criteria to determine how we should optimally diagnose sarcopenia in patients with heart disease. Then, I will identify patients who are referred for heart surgery and have low muscle mass and strength (sarcopenia) to test a targeted treatment - a specialized protein supplement beverage - which was designed to stimulate muscle building in older adults, and, I hypothesize, will improve their recovery of physical function and other outcomes after the heart surgery procedure.
Competitiondate
201512
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Afilalo, Jonathan
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~